

## MEDIA ALERT

The logo for EuroEyes, featuring the word "EuroEyes" in white sans-serif font on a dark blue rectangular background.

**EuroEyes International Eye Clinic Limited**  
德視佳國際眼科有限公司  
(Stock Code: 1846.HK)

### **Foreign Exchange Movements Have No Impact on Daily Operation of EuroEyes**

**Hong Kong, 6 December 2022** – In light of recent news about fluctuating foreign exchange rates, [EuroEyes International Eye Clinic Limited](#) (“EuroEyes” or the “Company”, together with its subsidiaries, the “Group”, HKEX: 1846), a leading global vision correction service provider, wishes to inform its shareholders and potential investors that foreign exchange rate movements have no impact on the day-to-day operation of the Group.

EuroEyes operates primarily in Europe and China and conducts business in the respective markets’ local currencies, including paying staff salaries and purchasing supplies and equipment. The Group maintains a healthy cash flow with no debt nor negative interest rate of the company’s cash deposits. This means changes in foreign exchange rates, such as the appreciation of the US dollar, does not affect its daily business dealings.

As a company listed on the Hong Kong stock exchange, the Group reports its financial numbers in Hong Kong dollar terms, which is when foreign exchange rates would come into play. While this would have an optical impact on the Group’s financial performance, it would like to reiterate that external factors such as foreign exchange rate movements, which are beyond its control, is not a reflection of the strength and continued business growth of the Group.

EuroEyes is committed to delivering value to its shareholders. As part of its strategy to grow sustainably, the Group continuously optimises its cost control measures that helps maintain a healthy cost structure. In September 2022, EuroEyes announced it has [signed a four-year medical equipment supplier agreement with Carl Zeiss AG](#) that allows the Group to secure long-term stable pricing on goods and equipment that it procures from them, which would help EuroEyes weather the inflationary environment and potentially benefit its patients and shareholders. The agreement also gives the Group access to the most advanced and relevant equipment from Carl Zeiss, including lenses, laser systems, as well as opportunities to embark on scientific collaborations that will enable EuroEyes to equip its clinics globally with state-of-the-art technologies, further advancing its business worldwide.

###

#### **About EuroEyes International Eye Clinic Limited**

EuroEyes was established in 1993 and is one of the leading brands in the vision correction industry that combines German ophthalmology excellence and over 25 years of experience with individualised customer care. EuroEyes is one of the few eye clinic groups with a far-reaching geographical coverage, with operations in Germany, Denmark and the PRC. The Group’s vision correction services include (i)

refractive laser surgery (which includes ReLEx smile and Femto LASIK); (ii) phakic lens (ICL) surgery; (iii) lens exchange surgery (which includes the monofocal and trifocal lens exchange surgery) and (iv) others (which include PRK/LASEK and ICRS implantation).

For more information, please visit [www.euroeyes.hk](http://www.euroeyes.hk).

**Media inquiries:**

**Hume Brophy Communications:**

Jane Hung, Connie Chan – [euroeyeshk@humbrophy.com](mailto:euroeyeshk@humbrophy.com)